Alisopimuksin

Alisopimuksin is a synthetic opioid analgesic developed by the pharmaceutical company Takeda Pharmaceutical Company Limited. It is a mu-opioid receptor agonist, meaning it binds to and activates the mu-opioid receptors in the brain, which are responsible for the analgesic (pain-relieving) effects of opioids. Alisopimuksin is available in the form of tablets and is used to manage moderate to severe pain in adults. It is typically prescribed for conditions such as cancer pain, post-operative pain, and chronic pain. The drug is known for its rapid onset of action, with pain relief usually occurring within 30 minutes of administration. Alisopimuksin is also known for its long duration of action, with pain relief lasting up to 12 hours. However, like all opioids, alisopimuksin carries a risk of dependence and should be used with caution. It is important to follow the prescribed dosage and duration of use, and to seek medical advice if experiencing any side effects or concerns about the drug. Alisopimuksin is not approved for use in the United States, but it is available in several other countries, including Japan, where it is marketed under the brand name Alisopim.